middle.news
Can Mayne Pharma’s Women’s Health Surge Offset Dermatology Challenges?
8:52am on Monday 22nd of December, 2025 AEDT
•
Healthcare
Read Story
Can Mayne Pharma’s Women’s Health Surge Offset Dermatology Challenges?
8:52am on Monday 22nd of December, 2025 AEDT
Key Points
Women’s Health prescriptions up 15% with strong growth in key brands
Dermatology segment gross margin improves to 64% after new product launches
Group total direct contribution down 7.3% due to increased marketing and one-off credits
Underlying EBITDA halved to $11.5 million amid higher expenses and reduced contributions
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE